Strategic Performance and Operational Drivers
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Revenue growth was primarily driven by a 48% increase in ZELSUVMI prescription units, reflecting strong market adoption of the first and only FDA-approved at-home treatment for Molluscum Contagiosum (MC).
Management attributes the 81.3% unit increase within a major PBM to a strategic contract executed late last year, which significantly reduced patient friction and accelerated prescriber acquisition.
The company achieved top-line growth while simultaneously improving operational efficiency, reducing wholesale inventory days on hand by approximately three days during the quarter.
Strategic positioning is bolstered by new expert consensus guidelines published in the Journal of Drugs in Dermatology, which recognize ZELSUVMI as the sole at-home clinical option for pediatric MC.
Operational focus is expanding toward a multi-product commercial strategy, leveraging existing sales infrastructure to prepare for the upcoming launches of XEPI and Xeglyze.
Management addressed a technical accounting restatement related to convertible debt fair value, clarifying that the non-cash adjustment has no impact on revenue, cash flow, or underlying business economics.
Strategic Outlook and Launch Sequencing
The company expects ZELSUVMI gross-to-nets to shift from 29.6% toward the mid-30% range as it pursues additional payer contracts to further reduce patient access friction.
Management anticipates XEPI will launch in Q1 2027, following the establishment of manufacturing processes and necessary FDA approval for site changes.
Xeglyze commercialization is projected for Q3 2027, with manufacturing ramp-up and API production expected to begin in earnest by mid-2026.
Future growth strategy relies on leveraging the existing 67-territory sales force to market XEPI and Xeglyze, targeting high call overlap with current ZELSUVMI prescribers.
Q3 performance is expected to remain stable despite typical summer seasonality, supported by recent weekly prescription highs exceeding 1,000 units.
Operational Risks and Structural Adjustments
A $0.9 million inventory write-off occurred due to out-of-spec API testing results; management confirmed the procedural cause was identified and subsequent manufacturing meets standards.
SG&A expenses included a $5.3 million one-time non-recurring sales-based milestone payment related to the ZELSUVMI license.
The company restated Q1 2026 financials to correct the fair value measurement of convertible notes following a subordination agreement, though this was a non-cash accounting adjustment.
Normalized cost of goods is expected to reach a mid-single-digit percentage of WAC price once the remaining stepped-up API inventory is consumed over the next 12 to 15 months.
